## **AUTHORS GUIDELINE**

#### **Submission**

The publication language of the EJLS is English. Please perform spell and grammar check of the article. Authors, for whose native language is not English, are strongly encouraged to have their manuscript carefully edited prior to submission. Before submitting, all contributors must agree and sign the Copyright Transfer Form. The following five documents must be uploaded for article submission. If you receive a message indicating that you are not authorized to download these documents, you can access them through the manuscript submission system.

- Copyright Transfer Form
- Title Page
- Manuscript
- Suggested Reviewers Form
- Cover Letter

All articles should be submitted online, unless otherwise instructed by the editors. Our online submission system guides you stepwise through the process of entering your article details and uploading your files. After the submission, the manuscripts will be edited according to the EJLS submission format and authors may be requested for some corrections or for addition of any missing information. There is no submission or page charges for the EJLS.

The main article types are as follows:

## Research Articles

The EJLS considers all original research articles provided that the work reports scientifically sound experiments and provides a substantial amount of new information. The main text of original articles should be structured according to the "Article Structure" title given below.

#### **Review Articles**

Review articles provide an overview of recent updates on the literature of any field within life sciences. Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed.

# **Short Communication**

Short communications are suitable for the presentation of research that extends previously published research, including the reporting of additional controls and confirmatory results in other settings, as well as negative results. Short communications may be edited for clarity or length and may be subject to peer review at the editors' discretion. Short reports of research work will be peer reviewed.

# **Case Report**

A case report describes a clinical case with an emphasis on the clinical situation and outcome in relation to an interventional procedure. This can be compared to a grand clinical round.

#### **General Rules**

All headings must be numbered consecutively and hierarchically. Please avoid using more than three levels of headings. The proposed location of figures and tables must be indicated in the main text. Within the article, avoid the use of footnotes and endnotes.

Symbols, abbreviations and conventions in papers must follow the recommended SI Units. A single space must be placed between the number and the unit. Abbreviations must be defined in brackets after their first mention in the text in accordance with internationally agreed rules.

Mathematical symbols and formulae must be typed in Microsoft Word and any other application or program must not be used. If necessary, they should also be numbered consecutively and uploaded separately in jpeg format. Equation numbers must be in parentheses and numbered consecutively. All equation numbers must appear on the right-hand side of the equation and must be referred to within the text.

Please use a decimal point rather than a comma in numbers (i.e. 3.142 not 3,142). Write numbers less than 1 as 0.54 not as .54. Report summary rather than raw data. Do not use "average". Instead, specify which type of "average" you report (mean, median, mode, etc.). Present means and standard deviation/standard error in the format  $X \pm SD/SE$  unit (i.e., mean body weight =  $6.38 \pm SD$  1.29 kg). Present ranges as "range: 15-29".

## **Figures and Tables**

The total number of tables and figures must not exceed 10. If your figure is created in a Microsoft Office application then please upload the original document. Submit each figure as a separate file. Figures must have a minimum 300 dpi resolution. Figures should be properly sized and cropped according to the EJLS page format or column size.

Please do not supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors. Ensure that each figure has a caption with a figure number.

Submit tables as editable text in Microsoft Word, not as images. Table headings should be given above the table and written in sentence case. Please avoid using vertical borders. Ensure that each table has a caption with a table number.

# **Style**

Check out the EJLS manuscript template for detailed information. All manuscripts must be uploaded in editable Microsoft Word format with separately added figures/table files. Do not mix different font styles in text and figures/tables. Use Times New Roman Font with 12-point font size in text and 10 point in tables. Use 1.5 line spacing, do not leave extra space between paragraphs. Preferably use left and right justified text, do not use any right or left identation. Use clear black text on a white background. All pages must be numbered consecutively.

#### **Plagiarism**

All submissions are screened by a similarity detection software (iThenticate by CrossCheck) at any point during the peer-review or production process. Even if you are the author of the phrases or sentences, the text should not have unacceptable similarity with the previously published data.

## Declaration of generative AI in scientific writing

Authors are not permitted to use generative artificial intelligence (AI) or AI-assisted technologies in the writing process. All parts of the manuscript must be written, reviewed, and edited solely by the authors themselves. AI and AI-assisted technologies must not be listed as an author or co-author, nor cited as a source. By submitting a manuscript to the *European Journal of Life Science*, the author(s) declare that no part of the manuscript has been generated or edited using generative AI technologies and that they fully comply with this policy.

- Any violation will be considered a breach of publication ethics and may result in rejection of the submission or retraction of the published article.
- Authors remain fully responsible for the originality, accuracy, and integrity of their work.

#### **Article Structure**

Research Papers should be organized as follows: Title, Author names and affiliations, Corresponding author information, Abstract, Keywords, Introduction, Materials and methods, Results and Discussion, Conclusion, Author contributions, Acknowledgments (if any), Ethics committee approval (if necessary), Conflict of interest declaration, References. These rules are a bit more flexible in review articles.

#### Title

A concise and informative title is required. Do not use any abbreviations and formulae in the title of the manuscript. The title of the manuscript must be written in sentence case except for the first word and proper nouns.

## **Author Names and Affiliations**

Indicate clearly the name(s) and surname(s) of each author. Present the authors' affiliation addresses below the names. Indicate all affiliations with a superscript number.

# **Corresponding Author Information**

Indicate clearly who will handle correspondence at all stages of publication. Corresponding Author details including name, complete address, phone, fax, and e-mail must be added. The first author will be considered as the corresponding author when no corresponding author is assigned.

## Abstract

A concise and factual abstract of maximum 250 words is required. The abstract should state the purpose of the research, the experimental studies, the principal results and the major conclusions. Do not cite any references and do not use any abbreviations in the abstract.

# Keywords

Immediately after the abstract, maximum 5 keywords should be stated in alphabetical order. Keywords must be carefully selected to facilitate the readers' search.

## Introduction

The introduction section of the articles (particularly research articles) should include the following topics;

- establish current knowledge of the field,
- summarize previous research, providing the wider context and background and the importance of the current study,
  - set the stage for the present research, indicating gaps in knowledge and presenting the research question,
  - introduce present research, stating its purpose and outlining its design.

## **Material and Methods**

The Methods should describe clearly how you carried out your study. Provide sufficient details such as study design and data collection to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference.

#### **Results and Discussion**

A combined Results and Discussion section is often appropriate; but optionally can be written separately. Provide a concise and precise description of the all experimental data, their interpretation as well as the experimental conclusions that can be drawn. Discussion should explore the significance of the results of the work, not repeat them. The P values and/or the specific statistical tests performed for each experiment should be included to the results and discussion section in the appropriate figure legend or main text. Results should include the name of the statistical test, followed by a colon, the test statistic and its value, degrees of freedom or sample size (depending on which is most appropriate for that test), and the P value, with indication if it is one-or two-tailed (unless you address this issue in the methods).

#### Conclusion

The conclusion section of the articles (particularly research articles) should include the following topics;

- principles, relationships, and generalizations inferred from the results (but not a repetition of the results),
- any exceptions to or problems with those principles, relationships, and generalizations, as indicated by the results
- agreements or disagreements with previously published work,
- theoretical implications and possible practical applications of the work,
- conclusions drawn (especially regarding significance).

### **Author Contributions**

Articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used:

Concept, Design, Supervision, Materials, Data Collection and/or Processing, Analysis and/or Interpretation, Literature Search, Writing, Critical Reviews. Initials of the contributing authors (i.e. AA, BB) should be given after these specified titles and all of them must be filled.

# Acknowledgments

Acknowledgments should include sources of support, grants, disclaimers, names of those who contributed but are not authors, etc. The names of funding organizations should be written in full. If no funding or help has been provided for the research, please include the "None" statement.

#### **Conflict of Interest Declaration**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence their work. If no conflict exists, the authors should include the "The authors declare no conflict of interest." statement under this section.

# **Ethics Committee Approval**

When reporting experiments conducted with humans indicate that the procedures were in accordance with ethical standards set forth by the committee that oversees human experimentation. Approval of research protocols by the relevant ethics committee, in accordance with international agreements.

Helsinki Declaration of 1964, revised 2013 available at

https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Guide for the Care and use of Laboratory Animals available at www.nap.edu/catalog/5140.html is required for all experimental, clinical, and drug studies. Patient names, initials, and hospital identification numbers should not be used. Manuscripts reporting the results of experimental investigations conducted with humans must state that the study protocol received institutional review board approval and that the participants provided informed consent.

#### References

Citation in text must be numbered as [1] or [1-5]. Please ensure that each reference cited in the text is also present in the reference list. References should be accurate and numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section with the DOI link. All authors must be cited and there should be no use of the phrase et al. No references should be given for the abstract section. Date of access should be provided for online citations. To assist authors in the manuscript preparation process, we have prepared an EndNote template file that ensures compatibility with the journal's reference formatting requirements. Authors are encouraged to use this template to facilitate accurate and consistent citation formatting.

See below few examples of references listed in the EJLS style.

## Journal

- 1. Osmaniye D, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Synthesis and characterization of new piperazine-dithiocarbamate compounds as potent MAO-A inhibitors. Eur J Life Sci. (2022);1(1):1-7. https://doi.org/10.55971/EJLS.1089254
- 2. Rouzer CA, Marnett LJ. Structural and chemical biology of the interaction of cyclooxygenase with substrates and non-steroidal anti-inflammatory drugs. Chem Rev. (2020);120(15):7592-7641. https://dx.doi.org/10.1021/acs.chemrev.0c00215
- 3. Krammer, F. SARS-CoV-2 vaccines in development. Nature. (2020);586:516–527. https://doi.org/10.1038/s41586-020-2798-3

Book

4. Wilson CG, Crowley PJ. Controlled release in oral drug delivery. New York: Springer; (2011). ISBN:978-1-4614-1003-4

# **Book Chapter**

- 5. Ağalar HG. Chapter 7 Vaccinium macrocarpon Ait. and urinary tract infections. In: Atta-ur-Rahman, editor. Studies in Natural Products Chemistry. Amsterdam: Elsevier; (2022). p. 267-288. ISBN:978-0-323-91250-1
- 6. Verma R, Raj S, Berry U, Ranjith-Kumar CT, Surjit M. Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges. In: Sobti RC, Lal SK, Goyal RK, editors. Drug Repurposing for Emerging Infectious Diseases and Cancer. Singapore: Springer; (2023). p. 451–478.

ISBN: 978-981-19-5398-9

#### Patent

- 7. Wong HL, Narvekar M, Xue HY, inventors; Temple University, assignee. Nanospheres for therapeutic agent delivery. United States patent no 9724304. (2017).
- 8. Yılmaz N, Altıntop MD, Akalın Çiftçi G, Sever B, inventors; Anadolu University, assignee. New triazole and triazolothiadiazine derivatives exerting cytotoxic and apoptotic effects on A549 cells through Akt inhibition. Turkish patent no 2020/10296. (2022).

#### **Thesis**

- 9. Arora HC. Doxorubicin-Nanocarriers Enhance Doxorubicin Uptake and Clathrin-Mediated Endocytosis in Drug-Resistant Ovarian Cancer Cells [Ph.D.]. Illinois: Northwestern University; (2012).
- 10. Finn NA. Role of redox systems in doxorubicin metabolism and doxorubicin-mediated cell signaling: a computational analysis [Ph.D.]. Atlanta: Georgia Institute of Technology; (2011).

## **Conference Proceedings**

11. Altıntop MD, Temel HE, Özdemir A. A series of imidazole derivatives as new anticholinesterase agents. 13th International Conference on Alzheimer's and Parkinson's Diseases (ADPD 2017); March 29-April 2, 2017; Vienna-Austria.

## Website

12. World Health Organization (2023, February 11). Cholera – Global situation. Retrieved April 4, 2023, from https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON437